Clinical Trial Update: Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the safety and tolerability of TAR-200 in combination with nivolumab in muscle-invasive bladder cancer; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• TAR-200
• nivolumab (nivolumab)

Snippet

Sponsor: Taris Biomedical LLC | Conditions: Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A | Phase 1 | Status: TERMINATED